Lorinden S, 15 g

Lorinden S is a drug with antibacterial, antifungal and anti-inflammatory effects for external use.

Flumethasone is a synthetic two-fluorinated GCS for external use. It has anti-inflammatory, anti-allergic, antipruritic, anti-edematous and vasoconstrictor effects. 

When exposed to the skin, it prevents the marginal accumulation of neutrophils, which leads to a decrease in inflammatory exudate and the production of lymphokines, inhibition of the migration of macrophages, a decrease in the processes of infiltration and granulation. Reduces the production of prostaglandins and leukotrienes by inhibiting the activity of phospholipase A2 and reducing the release of arachidic acid from the phospholipids of the cell membrane. 

It causes a reduction in the basic substance of connective tissue, weakens proliferative and exudative reactions in the skin. It is an inhibitor of cellular kinins with proteolytic activity.

Clioquinol (iodochloroxyquinoline) is a derivative of 8-hydroxyquinolines. It is active against dermatophytes, yeast fungi (Microsporum spp., Trichophyton spp., Candida albicans) and gram-positive bacteria (Staphylococcus spp., Enterococcus spp.). 

Enhances the antiexudative effect of flumethasone.

As a result of the combined action of flumethasone and clioquinol (iodochloroxyquinoline), the drug suppresses the development of inflammatory and allergic reactions from the skin, complicated by bacterial and fungal infections.

The fatty base of Lorinden C ointment has an emollient, water-repellent effect and forms a protective film that protects the skin from external moisture. Due to the peculiarities of the ointment base, the drug can be used in patients with dry and thin skin.

Allergodermatoses complicated by the addition of a bacterial infection caused by microorganisms sensitive to clioquinol:

• dermatitis (including allergic, contact, professional, seborrheic, solar);
• eczema;
• psoriasis (especially chronic cases; including psoriasis of the scalp);
• erythema multiforme;
• erythroderma;
• atopic dermatitis (common neurodermatitis);
• pruritus;
• dermatoses that do not respond to GCS therapy (including lichen planus, discoid lupus erythematosus);
• hives;
• secondary infections with insect bites.

Bacterial and fungal skin infections complicated by the development of local allergic reactions:

• impetigo;
• infected diaper rash;
• dermatomycosis, actinomycosis, blastomycosis, sporotrichosis.

• Hypersensitivity to drug components.
• Viral skin diseases (herpes, chickenpox), skin tuberculosis, skin manifestations of syphilis, neoplasms and precancerous skin conditions (skin cancer, nevus, atheroma, epithelioma, melanoma, hemangioma, xanthoma, sarcoma). 
• Acne vulgaris and rosacea, perioral dermatitis, trophic ulcers of the leg associated with varicose veins, conditions after vaccination. 
• Skin infections (for occlusive dressing).
• Do not use the drug in children under 10 years of age.

Contact eczema;

allergy symptoms (mainly in persons with existing allergic diseases - eczema, leg ulcer, etc.);

exacerbation of already existing changes with ordinary or rosacea; papular or erythematous manifestations resistant to any methods of treatment (with prolonged use);

post-steroidal acne, purpura, telangiectasia, skin atrophy and stretching, perioral dermatitis, dry mouth, hypopigmentation.

During therapy with Lorinden C, vaccination and immunization should not be carried out due to the immunosuppressive effect of the drug.

The drug should not be administered in combination with other drugs for external use.

When the drug is absorbed into the systemic circulation, flumethasone reduces the effectiveness of insulin, oral hypoglycemic agents, antihypertensive drugs, anticoagulants, and reduces the concentration of salicylates and praziquantel in serum.

When used together, the risk of developing side effects of androgens, estrogens, oral contraceptives, anabolic steroids (hirsutism, acne) increases;

antipsychotics, bucarban, azathioprine (cataract);

anticholinergics, antihistamines, tricyclic antidepressants, nitrates (glaucoma); diuretics (hypokalemia), cardiac glycosides (digitalis intoxication).

The drug should not be used for more than 2 weeks. If there is a need for a dressing, then a breathable dressing should be used. With excessive lichenization and hyperkeratosis, the ointment is applied only under an occlusive dressing once every 24-48 hours. Do not use the drug for more than 1 week.

If not necessary, do not use more than 2 g of ointment during the day.

In adolescents after 10 years, use only in exceptional cases on limited areas of the skin, avoid applying the drug to the skin of the face.

Overdose cases are rare.

Symptoms: in case of improper, frequent or prolonged use in significant amounts over large areas, systemic side effects of GCS may occur.

Treatment: gradual withdrawal of the drug; symptomatic therapy.

Use with caution in case of skin mycoses.

ointment